Notizia - Recent Pharma, Healthcare and Biotech Happenings

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare disease. GW received the voucher when FDA approved its cannabinoid medicine Epidiolex for treating seizures. BioMed Realty acquires Emeryville Center for Innovation BioMed Realty-a blackstone portfolio company has acquired Emeryville Center for Innovation for USD 135 million. This campus acquisition of around 250,000 square foot, six-story life science...